Open Access. Powered by Scholars. Published by Universities.®
Pharmacoeconomics and Pharmaceutical Economics Commons™
Open Access. Powered by Scholars. Published by Universities.®
- Discipline
-
- Pharmacy Administration, Policy and Regulation (3)
- Administrative Law (1)
- Bioethics and Medical Ethics (1)
- Business (1)
- Chemicals and Drugs (1)
-
- Commercial Law (1)
- Economics (1)
- Food and Drug Law (1)
- Health Economics (1)
- Health Information Technology (1)
- Health Law and Policy (1)
- Insurance (1)
- Intellectual Property Law (1)
- Law (1)
- Mathematics (1)
- Pharmaceutical Preparations (1)
- Physical Sciences and Mathematics (1)
- Social and Behavioral Sciences (1)
- Institution
- Publication
- Publication Type
Articles 1 - 5 of 5
Full-Text Articles in Pharmacoeconomics and Pharmaceutical Economics
Will Reducing Drug Prices Slow Innovation?, Gregory Vaughan, Fred Ledley
Will Reducing Drug Prices Slow Innovation?, Gregory Vaughan, Fred Ledley
Mathematical Sciences Faculty Publications
The pharmaceutical industry has long argued that high drug prices reflect the high cost of innovation and that reducing drug prices would necessarily slow the pipeline of new drugs. These arguments have been bolstered by studies of large pharmaceutical companies showing statistical associations between the projected market size or revenue for pharmaceutical products and research & development (R&D) activity. Our analysis recognizes the increasingly important role of small biopharmaceuticals in drug development , companies that typically have little revenue and negative earnings, but are now responsible for more than 40% of new drug approvals. We examine the relationship between changes …
Will Reducing Drug Prices Slow Innovation?, Gregory Vaughan, Fred Ledley
Will Reducing Drug Prices Slow Innovation?, Gregory Vaughan, Fred Ledley
Natural & Applied Sciences Faculty Publications
The pharmaceutical industry has long argued that high drug prices reflect the high cost of innovation and that reducing drug prices would necessarily slow the pipeline of new drugs. These arguments have been bolstered by studies of large pharmaceutical companies showing statistical associations between the projected market size or revenue for pharmaceutical products and research & development (R&D) activity. Our analysis recognizes the increasingly important role of small biopharmaceuticals in drug development , companies that typically have little revenue and negative earnings, but are now responsible for more than 40% of new drug approvals. We examine the relationship between changes …
Critical Analysis Of The Confounding Of Clinical Trials, Eleanor L. Jordan
Critical Analysis Of The Confounding Of Clinical Trials, Eleanor L. Jordan
Senior Honors Projects, 2010-2019
To provide a comprehensive overview of issues confounding clinical trials, Chapter 2 will discuss the parties involved in the research and development of medications and detail the individual responsibilities of each. However, the ambition of these individual entities often produces a conflict of interest especially when profits are involved [9]. Organizations and individuals such as insurance corporations, pharmaceutical companies (sponsors), pharmacy benefit managers, investigators (doctors/medical professionals) and most importantly patients, are all involved in carrying out clinical research and have definitive responsibilities they are required to follow for unbiased results. However, many rules are overlooked and biases go unrecorded causing …
Making Do In Making Drugs: Innovation Policy And Pharmaceutical Manufacturing, W. Nicholson Price Ii
Making Do In Making Drugs: Innovation Policy And Pharmaceutical Manufacturing, W. Nicholson Price Ii
Law Faculty Scholarship
Despite increasing recalls, contamination events, and shortages, drug companies continue to rely on outdated manufacturing plants and processes. Drug manufacturing’s inefficiency and lack of innovation stand in stark contrast to drug discovery, which is the focus of a calibrated innovation policy that combines patents and FDA regulation. Pharmaceutical manufacturing lags far behind the innovative techniques found in other industries due to high regulatory barriers and ineffective intellectual property incentives. Among other challenges, although manufacturers tend to rely on trade secrecy because of the difficulty in enforcing patents on manufacturing processes, trade secrecy provides limited incentives for innovation. To increase those …
Pharmaceutical Counterfeiting And The Rfid Technology Intervention, Alberto Coustasse, Cody Arvidson, Phil Rutsohn
Pharmaceutical Counterfeiting And The Rfid Technology Intervention, Alberto Coustasse, Cody Arvidson, Phil Rutsohn
Management Faculty Research
Both nationally and internationally, pharmaceutical counterfeiting has become a problem that is threatening economic stability and public health. The purpose of the present research study review was to analyze the scope and severity of pharmaceutical counterfeiting and to establish if the implantation of the Radio Frequency Identification Device (RFID) model can more efficiently be used within the pharmaceutical supply chain to reduce the problem counterfeit drugs impose on public health and international economic stability. Results indicated that implementing the RFID model for tracking drugs at the item level in the pharmaceutical supply chain has potential to alleviate the scope of …